Change of registered office and principal place of business

Invion Limited (ASX:IVX) wishes to advise that, effective 1 October 2013, the registered office and principal place of business for the Company will be:

Invion Limited
c/- McCullough Robertson Lawyers
Level 11, 66 Eagle Street
Brisbane, QLD, 4000

As of this date, contact details for the Company are:

Invion Limited
GPO Box 1557
Brisbane, QLD, 4001
Telephone: + 61 7 3295 0500
Facsimile: + 61 7 3295 0599


FOR MORE INFORMATION CONTACT:
Melanie Farris, Company Secretary P: +61 7 3295 0500 E: investor@invion.com.au

About Invion Limited
Invion is a clinical-stage life sciences company focussed on the development of treatments for major opportunities in the inflammatory diseases market including asthma and COPD ($34B) and systemic lupus erythematosus (lupus) (to $4B). Invion has two drug assets in three FDA-regulated, phase II clinical trials currently underway in the US. INV102 (nadolol) is a beta blocker (beta adrenergic inverse agonist) currently used in the treatment of high blood pressure and migraine that is being repurposed to treat chronic inflammatory airway diseases (e.g. asthma and COPD). The US National Institutes of Health is funding Invion’s phase II asthma clinical trial in excess of USD$4M, and a second phase II trial in chronic bronchitis (smoking cessation) is also underway. INV103 (ala-Cpn10) is a modified naturally occurring human protein shown to reduce IL-6, a key marker in the chronic inflammatory disease, lupus. Invion has operations in Australia and the United States.

Posted in ASX Releases